1.Reduction of viral burden (by 50%) based on the natural log Cycle threshold (Ct) value of the reverse transcriptase- quantitative PCR test (RT-PCR) for SARS-COV-2.(Specimen will be a nasopharyngeal swab or aspirate. Viral burden will be calculated using the Ct values as done in BLAZE-1 study protocol. [Baseline; day 06 and day 10 from the date of intervention.]2.Clinical progression of the patient using WHO Clinical Progression Scale [Day 03; 06; 10; 14; 21 and 28 from the date of intervention (remote monitoring if discharged)]3.Percentage of participants who experience side effects recorded by the patient on data sheet for assessment of symptoms and side effects. [Day of intervention; days 03; 06; 10 and 14] [ ] [] [] [ ] [ ] [ ] [ ] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] []

1.Reduction of viral burden (by 50%) based on the natural log Cycle threshold (Ct) value of the reverse transcriptase- quantitative PCR test (RT-PCR) for SARS-COV-2.(Specimen will be a nasopharyngeal swab or aspirate. Viral burden will be calculated using the Ct values as done in BLAZE-1 study protocol. [Baseline; day 06 and day 10 from the date of intervention.]2.Clinical progression of the patient using WHO Clinical Progression Scale [Day 03; 06; 10; 14; 21 and 28 from the date of intervention (remote monitoring if discharged)]3.Percentage of participants who experience side effects recorded by the patient on data sheet for assessment of symptoms and side effects. [Day of intervention; days 03; 06; 10 and 14] [ ] [] [] [ ] [ ] [ ] [ ] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] [] []